These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31975438)
1. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438 [TBL] [Abstract][Full Text] [Related]
2. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. Kwo PY; Puenpatom A; Zhang Z; Hui SL; Kelley AA; Muschi D PLoS One; 2019; 14(8):e0218759. PubMed ID: 31437170 [TBL] [Abstract][Full Text] [Related]
4. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C. Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789 [TBL] [Abstract][Full Text] [Related]
5. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals. Yoh K; Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Aizawa N; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057827 [TBL] [Abstract][Full Text] [Related]
6. Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C virus. Endo K; Sato T; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y Nutrition; 2022 Sep; 101():111699. PubMed ID: 35700590 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501 [TBL] [Abstract][Full Text] [Related]
8. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685 [TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085 [TBL] [Abstract][Full Text] [Related]
10. Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system. Joshi P; Atherton A J Gastroenterol Hepatol; 2019 Dec; 34(12):2173-2178. PubMed ID: 31062412 [TBL] [Abstract][Full Text] [Related]
11. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
12. Safety of Direct-Acting Antiviral Therapy for Renal Function in Post-Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response: A Single-Center Study. Kawagishi N; Nakamura A; Takayama T; Haga I Ther Apher Dial; 2020 Apr; 24(2):184-188. PubMed ID: 31290282 [TBL] [Abstract][Full Text] [Related]
13. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H Oncology; 2016; 91(6):341-347. PubMed ID: 27694754 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844 [TBL] [Abstract][Full Text] [Related]
15. Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients. Lashen SA; Shamseya MM; Madkour MA; Aboufarrag GA Liver Int; 2019 May; 39(5):835-843. PubMed ID: 30549417 [TBL] [Abstract][Full Text] [Related]
16. Incidence of Post-Liver Transplant Hepatic Dysfunction After Sustained Virologic Response Following Direct-Acting Anti-Hepatitis C Therapy. Jain A; Riley TR; Krok KL; Schreibman I; Karamchandani DM; Liao X; Tian Y; Dohi T; Kadry Z Exp Clin Transplant; 2020 Jun; 18(3):345-352. PubMed ID: 30295586 [TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965 [TBL] [Abstract][Full Text] [Related]
18. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy. Toyoda H; Kumada T; Tada T; Yama T; Mizuno K J Gastroenterol Hepatol; 2018 Jun; 33(6):1264-1270. PubMed ID: 29164675 [TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625 [TBL] [Abstract][Full Text] [Related]
20. Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study. Peschel G; Moleda L; Baier L; Selgrad M; Schmid S; Scherer MN; Müller M; Weigand K Transplant Proc; 2018 Jun; 50(5):1444-1450. PubMed ID: 29880368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]